About Anteris Technologies

Anteris Technologies (ASX:AVR) is a structural heart company focused on delivering clinically superior solutions that create life-changing outcomes for patients. Anteris Technologies has developed DurAVR™ THV, which is a novel first-in-class biomimetic valve made from a single piece of native-shaped tissue. It’s designed to mimic the performance of a pre-disease human aortic valve. It’s also created ADAPT®, which is a patented anti-calcification tissue technology. ADAPT® tissue has been used clinically for over 10 years and distributed for use in over 50,000 patients worldwide.

Snapshot

Public AUOwnership

1999Year founded

88Employees

Queensland, AustraliaHead office

Loading Map...

Global footprint

Operations

All Locations

Australia

Products and/or services of Anteris Technologies

DurAVR™: DurAVR™ is a next-generation aortic valve replacement system that is currently in clinical trials. DurAVR™ is designed to provide patients with a more durable and longer-lasting valve replacement option.
ADAPT™: ADAPT™ is a proprietary tissue platform that is used to manufacture Anteris' products. ADAPT™ is designed to create tissues that are more biocompatible and durable than traditional tissues.
ComASUR™ Delivery System provides controlled deployment and accurate placement of the DurAVR™ THV valve, designed to achieve precise alignment with the heart’s native commissures to achieve ideal valve positioning.

Anteris Technologies executive team

Mr. Wayne Geoffrey PatersonVice Chairman & CEO
Mr. David St. DenisPresident & Director
Mr. Matthew McDonnellChief Financial Officer
Dr. Chris Meduri M.D., M.P.H.Chief Medical Officer & Member of Medical Advisory Board